

**REMARKS/ARGUMENTS**


The above amendments are to insert a cross-reference to the PCT application upon which this National Phase application is based, and to revise the claims from the originally published format to correct/remove multiple dependencies. In addition, the Abstract is presented on a separate sheet attached to this amendment.

Applicants await an early action on the merits. If the Examiner finds this case is not now in condition for allowance and believes that an interview prior to first action would be helpful in focussing and/or resolving issues, applicants request the Examiner to contact their representative at the telephone number listed below to arrange a telephonic or personal interview.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_

  
Leonard C. Mitchard  
Reg. No. 29,009

LCM:lfm  
901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

### **ABSTRACT OF THE DISCLOSURE**

A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a triglyceride oil containing both  $\gamma$ -linolenic acid and linolenic acid residues as triglyceride ester, the ratio of  $\gamma$ -linolenic acid to linolenic acid residues at the sn-2 position of the triglyceride being at least 0.8; the amount of  $\gamma$ -linolenic acid residues at the sn-2 position being at least 18 %, wherein the oil is administered at a dose sufficient to maintain or elevate TGF- $\beta$ 1 levels in the patient at a therapeutic level. Preferably the method is that wherein the therapeutic level is such as to produce a TGF- $\beta$ 1/TNF- $\alpha$  ratio of at least 0.5 in blood of a patient, after 18 months of daily dosing. Preferred oils are Borage or Mucor oils having at least 35 % of the sn-2 position fatty acid residues as  $\gamma$ -linolenic acid.